Processa presents NGC-Cap Phase 1b data at AACR; poster modified

Processa Pharmaceuticals, Inc.

David Young, President R&D, presented two abstracts at AACR 2024 on NGC-Cap and Project Optimus.
NGC-Cap Phase 1b data shows significantly increased 5-FU exposure and improved safety vs capecitabine.
The originally presented poster was subsequently modified; amended posters posted on company website.
Second abstract addresses optimal dose using Phase 1 and preclinical data under Project Optimus.
No specific numerical results disclosed in filing; detailed data available in website publications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.